As the BRAF inhibitor Vemurafenib was already available for BRAF V600E-mutated melanoma [26], proof of principle for clinical application in relapsed/refractory HCL was rapidly proven followed by that of Dabrafenib [27–29]. Here, BRAF is linked to melanoma.